In its first quarter results statement, Bristol Myers Squibb beat expectations on revenues, which increased 5% to $11.9 billion, although it posted a loss per s 25 April 2024
Like its rivals in the GLP-1 space, Eli Lilly (NYSE: LLY) continues to explore the potential of Zepbound (tirzepatide) in addressing the broad range of comorbid 18 April 2024
USA-based Nectero Medical has raised $96 million in a series D financing round led by Norwest Venture Partners, with significant investments also from Boston Sc 12 April 2024
Swiss drugmaker Novartis has revealed fresh plans to slim down its workforce, with a further 680 US and Swiss jobs to be cut from its development organizational 10 April 2024
Israel’s Teva Pharmaceutical Industries and Japanese drugmaker Daiichi Sankyo have been called out for breaches of the Association of the British Pharmaceutical 27 March 2024
Validating Novo Nordisk’s decision to research the cardiovascular impact of Wegovy (semaglutide), US authorities have said Medicare patients with heart problems 22 March 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.